Home > Dermatology > EADV 2022 > Pharmacotherapy in Hidradenitis Suppurativa: New Opportunities > Hidradenitis suppurativa: TYK2/JAK1 inhibitor shows promise

Hidradenitis suppurativa: TYK2/JAK1 inhibitor shows promise

Presented By
Prof. Alexandra Kimball, Harvard Medical School, MA, USA
EADV 2022
Out of 3 parallel tested kinase inhibitors, only brepocitinib met its primary efficacy endpoint of the Hidradenitis Suppurativa Clinical Response (HiSCR) score in a phase 2b study. The TYK2/JAK1 inhibitor also significantly reduced hidradenitis suppurativa (HS) flares. “We will look back on this meeting as an important milestone in our understanding of both the treatment and pathophysiology of HS,” Prof. Alexandra Kimball (Harvard Medical School, MA, USA) opened her talk on an umbrella study in HS [1]. This study design, novel to dermatology, was used to investigate 3 experimental agents with different modes of action versus placebo in a phase 2b trial (NCT04092452) on patients with moderate-to-severe HS, i.e. Hurley stages 2 and 3. A total of 194 participants were included in the different treatment and placebo groups of this umbrella study. “This design allows y...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on